Class effect? Glucose-lowerers linked to lower risk of heart failure
SGLT2-inhibitors are linked to a significantly lower risk of heart failure and premature death in patients with type 2 diabetes, say US and European researchers.
The CVD-REAL study of more than 300,000 patients with type 2 diabetes found SGLT2-inhibitor treatment was associated with a 39% relative risk reduction in heart failure and 51% in all-cause death compared with other glucose-lowering drugs.
The relative risk-reduction for the combined endpoint was 46%.
More than 50% of patients were treated with canagliflozin, followed by 42% for dapagliflozin and 5% for empagliflozin.